Resveratrol alone and its Combination with Pterostilbene amends Valproic Acid-Induced Autism in Swiss Albino Mice: Postnatal Model

Abstract

Objective: The present study was aimed to determine the therapeutic role of resveratrol and pterostilbene alone and combination in reversing the behavioral, biochemical, and histopathological alterations in valproic acid (VPA) induced oxidative stress and neuron damage in a postnatal model of autism. Method: 13 days old Swiss albino mice pups were randomly divided into five groups of six each, vehicle-treated group (1 mg/mL CMC), autistic group (VPA 400 mg/kg, sc), resveratrol (20 mg/kg, po), pterostilbene (10 mg/kg, po), and combination of resveratrol (10 mg/kg, po) + pterostilbene (5 mg/kg, po) group. On postnatal day (PND) 14, valproic acid (VPA) 400 mg/kg, sc, was administered to all except vehicle treated group. Resveratrol and/or pterostilbene was administered daily from PND 14 to 40. During the treatment, period various behavioural parameters were analysed. At the end of study, animals were sacrificed for biochemical estimations and histopathological study. Results: Single time administration of VPA at 400 mg/kg, sc, effectively induced autism. Treatment with resveratrol, pterostilbene, and the combination gave significant recovery in behavioral activity, biochemical, and histopathological alterations in mice when compared with the autistic group. Conclusion: Resveratrol and pterostilbene are good nutraceuticals in reversing the valproic acid-induced autistic deficits, in this study combination of resveratrol and pterostilbene provide superior results on recovery over individual therapy, it is suggested that this combination therapy potentiates the benefits and is more suitable for autism therapy.